4.3 Article

Postoperative complications following colectomy for ulcerative colitis: A validation study

Journal

BMC GASTROENTEROLOGY
Volume 12, Issue -, Pages -

Publisher

BIOMED CENTRAL LTD
DOI: 10.1186/1471-230X-12-39

Keywords

-

Funding

  1. Alberta Heritage Foundation for Medical Research (AHFMR)
  2. American Gastroenterological Association Foundation Student Research Fellowship Award
  3. Canadian Institute of Health Research (CIHR)
  4. M.S.I. Foundation
  5. AHFMR Health Scholar award

Ask authors/readers for more resources

Background: Ulcerative colitis (UC) patients failing medical management require colectomy. This study compares risk estimates for predictors of postoperative complication derived from administrative data against that of chart review and evaluates the accuracy of administrative coding for this population. Methods: Hospital administrative databases were used to identify adults with UC undergoing colectomy from 1996-2007. Medical charts were reviewed and regression analyses comparing chart versus administrative data were performed to assess the effect of age, emergent operation, and Charlson comorbidities on the occurrence of postoperative complications. Sensitivity, specificity, and positive/negative predictive values of administrative coding for identifying the study population, Charlson comorbidities, and postoperative complications were assessed. Results: Compared to chart review, administrative data estimated a higher magnitude of effect for emergent admission (OR 2.52 [95% CI: 1.80-3.52] versus 1.49 [1.06-2.09]) and Charlson comorbidities (OR 2.91 [1.86-4.56] versus 1.50 [1.05-2.15]) as predictors of postoperative complications. Administrative data correctly identified UC and colectomy in 85.9% of cases. The administrative database was 37% sensitive in identifying patients with >= 1Charlson comorbidity. Restricting analysis to active comorbidities increased the sensitivity to 63%. The sensitivity of identifying patients with at least one postoperative complication was 68%; restricting analysis to more severe complications improved the sensitivity to 84%. Conclusions: Administrative data identified the same risk factors for postoperative complications as chart review, but overestimated the magnitude of risk. This discrepancy may be explained by coding inaccuracies that selectively identifying the most serious complications and comorbidities.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Gastroenterology & Hepatology

Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease

Joshua Quan, Christopher Ma, Remo Panaccione, Lindsay Hracs, Nastaran Sharifi, Michelle Herauf, Ante Makovinovic, Stephanie Coward, Joseph W. Windsor, Lea Caplan, Richard J. M. Ingram, Jamil N. Kanji, Graham Tipples, Jessalyn K. Holodinsky, Charles N. Bernstein, Douglas J. Mahoney, Sasha Bernatsky, Eric Benchimol, Gilaad G. Kaplan

Review Gastroenterology & Hepatology

Most Placebo-Controlled Trials in Inflammatory Bowel Disease were Underpowered Because of Overestimated Drug Efficacy Rates: Results from a Systematic Review of Induction Studies

Paul Bahnam, Jurij Hanzel, Christopher Ma, Lily Zou, Neeraj Narula, Siddharth Singh, Brennan Kahan, Vipul Jairath

Summary: In clinical trials for inflammatory bowel disease, the efficacy of drug treatment is often overestimated, leading to smaller-than-expected treatment effects. These findings have important implications for trial design and drug development in this field.

JOURNAL OF CROHNS & COLITIS (2023)

Review Gastroenterology & Hepatology

Systematic review and meta-analysis of randomised controlled trials: Medical therapies for the treatment and prevention of pouchitis

Lotus Alphonsus, Theshani A. De Silva, Christopher Ma, John K. MacDonald, Jurij Hanzel, Melanie Beaton, Talat Bessissow, Maia Kayal, Rocio Sedano, Siddharth Singh, Vipul Jairath

Summary: A systematic review evaluated medical therapy for pouchitis treatment and prevention. The effects of vedolizumab and the De Simone formulation were found to be significant, while the effects of other interventions remain uncertain.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Review Pharmacology & Pharmacy

Targeting IL-23 for IBD: Rationale and Progress to Date

Sudheer K. Vuyyuru, Lisa M. Shackelton, Jurij Hanzel, Christopher Ma, Vipul Jairath, Brian G. Feagan

Summary: Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, is a group of complex immune-mediated disorders. Targeting the IL-23/Th-17 axis has shown effectiveness in the treatment of these diseases. IL-12/23 inhibitors have been approved for both Crohn's disease and ulcerative colitis, while IL-23p19 antagonists have shown better outcomes in psoriasis patients. Many specific IL-23p19 antagonists are being studied in the treatment of inflammatory bowel disease.

DRUGS (2023)

Article Gastroenterology & Hepatology

Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn's disease highlight earliest events of pathogenesis

Haim Leibovitzh, Sun-Ho Lee, Juan Antonio Raygoza Garay, Osvaldo Espin-Garcia, Mingyue Xue, Anna Neustaeter, Ashleigh Goethel, Hien Q. Huynh, Anne M. Griffiths, Dan Turner, Karen L. Madsen, Paul Moayyedi, A. Hillary Steinhart, Mark S. Silverberg, Colette Deslandres, Alain Bitton, David R. Mack, Kevan Jacobson, Maria Cino, Guy Aumais, Charles N. Bernstein, Remo Panaccione, Batia Weiss, Jonas Halfvarson, Wei Xu, Williams Turpin, Kenneth Croitoru

Summary: This study identified serum proteomic signatures associated with future development of Crohn's disease (CD), reflecting potential early biological processes of immune and barrier dysfunction.
Article Gastroenterology & Hepatology

Hospitalization Rates for Inflammatory Bowel Disease Are Decreasing Over Time: A Population-based Cohort Study

Michael J. Buie, Stephanie Coward, Abdel-Aziz Shaheen, Jayna Holroyd-Leduc, Lindsay Hracs, Christopher Ma, Remo Panaccione, Eric Benchimol, Charles N. Bernstein, Alain Bitton, Anthony R. Otley, Jennifer L. Jones, Sanjay K. Murthy, M. Ellen Kuenzig, Juan-Nicolas Pena-Sanchez, Laura E. Targownik, Harminder Singh, Antonio Avina-Zubieta, Gilaad G. Kaplan

Summary: Recent advances in IBD management have led to a decrease in hospitalization rates for IBD-related and non-IBD-related causes. The study observed a decline in all-cause hospitalization rates as well.

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

Health Care Disparities, Social Determinants of Health, and Emotional Impacts in Patients with Ulcerative Colitis: Results from a Global Ulcerative Colitis Narrative Patient Survey

Florence-Damilola Odufalu, Marla C. Dubinsky, Laurent Peyrin-Biroulet, Karoliina Ylanne, Allyson Sipes, Joseph C. Cappelleri, Leo J. Russo, Michelle Segovia, Sean Gardiner, Edward P. Johnson, Amy Mulvey, Remo Panaccione

Summary: This study investigated the impact of patient demographics and psychological comorbidities on disease management and health care experience in patients with ulcerative colitis, highlighting the need for better understanding and improvement of patient care.

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data

Silvio Danese, Jacinda Tran, Geert D'Haens, David T. Rubin, Nobuo Aoyama, Wen Zhou, Dapo Ilo, Xuan Yao, Yuri Sanchez Gonzalez, Remo Panaccione

Summary: This post hoc analysis evaluated the effects of upadacitinib on fatigue, bowel urgency, and abdominal pain in patients with ulcerative colitis. The results showed that upadacitinib induction treatment significantly reduced abdominal pain and bowel urgency, and also improved fatigue symptoms.

INFLAMMATORY BOWEL DISEASES (2023)

Article Multidisciplinary Sciences

Effect of vaccine dosing intervals on Omicron surrogate neutralization after three doses of BNT162b2

Martin A. Prusinkiewicz, Sadaf Sediqi, Ying Jie Li, David M. Goldfarb, Michael Asamoah-Boaheng, Nechelle Wall, Pascal M. Lavoie, Brian Grunau

Summary: This study investigated the impact of the interval between the first and second vaccine doses and between the second and third doses on the immunogenicity of the BNT162b2 vaccine. The results showed that longer intervals between doses were associated with increased immunogenicity. Increasing the interval between the second and third doses up to 8.9 months provided additional benefits in enhancing the immune response.

HELIYON (2023)

Review Health Care Sciences & Services

Design Principles in mHealth Interventions for Sustainable Health Behavior Changes: Protocol for a Systematic Review

Lin Yang, Angela Kuang, Claire Xu, Brittany Shewchuk, Shaminder Singh, Hude Quan, Yong Zeng

Summary: The aim of this study is to identify best practices for designing mHealth interventions targeting diet, physical activity, and sedentary behavior. The design characteristics of current mHealth tools, including personalization, real-time functions, and deliverable resources, will be summarized. The findings will serve as a foundation for developing mHealth tools for sustainable behavior change.

JMIR RESEARCH PROTOCOLS (2023)

Article Immunology

Mirikizumab for the treatment of moderate to severe ulcerative colitis

Jurij Hanzel, Christopher Ma, Vipul Jairath

Summary: Mirikizumab, an IL-23 inhibitor, is an effective and safe drug to treat moderate-to-severe ulcerative colitis (UC). Despite a growing number of available therapeutic options for UC, up to 50% of patients do not respond to initial treatment or lose response over time, highlighting the need for novel therapies. The IL-23 pathway has emerged as an important therapeutic target for UC. Mirikizumab is the first drug of its kind to receive approval for UC in Europe.

IMMUNOTHERAPY (2023)

Meeting Abstract Gastroenterology & Hepatology

Clinical response over 24 weeks for initial and delayed responders to induction therapy with risankizumab in Crohn's disease: data from the ADVANCE and MOTIVATE studies

R. Panaccione, I. Dotan, M. Ferrante, S. Danese, P. Bossuyt, K. Kligys, E. Neimark, J. Zambrano, X. Liao, G. D'Haens

JOURNAL OF CROHNS & COLITIS (2023)

Meeting Abstract Gastroenterology & Hepatology

Exploring duration of corticosteroid withdrawal in definitions of corticosteroid-free remission endpoints in ustekinumab clinical trials: results from the IM-UNITI, UNIFI, and SEAVUE trials

J. Panes, R. Panaccione, B. Sands, C. Gasink, C. Marano, T. Ma, T. Hoops

JOURNAL OF CROHNS & COLITIS (2023)

Article Gastroenterology & Hepatology

Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis

Remo Panaccione, Silvio Danese, Wen Zhou, Justin Klaff, Dapo Ilo, Xuan Yao, Gweneth Levy, Peter D. R. Higgins, Edward V. Loftus Jr, Su Chen, Yuri Sanchez Gonzalez, Carolyn Leonard, Xavier Hebuterne, James O. Lindsay, Qian Cao, Hiroshi Nakase, Jean-Frederic Colombel, Severine Vermeire

Summary: Upadacitinib demonstrates efficacy and safety for 16-week induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis. Patients without clinical response after 8 weeks' upadacitinib 45 mg induction therapy may benefit from an additional 8 weeks of therapy.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Correction Gastroenterology & Hepatology

Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme (Sep, jjac141, 2022)

William J. Sandborn, Geert R. D'Haens, Bruce E. Sands, Remo Panaccione, Siew C. Ng, Nervin Lawendy, Nicole Kulisek, Irene Modesto, Xiang Guo, Rajiv Mundayat, Chinyu Su, Ivana Vranic, Julian Panes

JOURNAL OF CROHNS & COLITIS (2023)

No Data Available